Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 8.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; VanderWalde, Ari; Andtbacka, Robert H I; Michielin, Olivier; Olszanski, Anthony J; Malvehy, Josep; Cebon, Jonathan; Fernandez, Eugenio; Kirkwood, John M; Gajewski, Thomas F; Chen, Lisa; Gorski, Kevin S; Anderson, Abraham A; Diede, Scott J; Lassman, Michael E; Gansert, Jennifer; Hodi, F Stephen; Long, Georgina V (2017). Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell, 170(6):1109-1119.e10.

Fan, Yiping; Lee, Seungjae; Wu, Gang; Easton, John; Yergeau, Donald; Dummer, Reinhard; Vogel, Peter; Kirkwood, John M; Barnhill, Raymond L; Pappo, Alberto; Bahrami, Armita (2016). Telomerase expression by aberrant methylation of the TERT promoter in melanoma arising in giant congenital nevi. Journal of Investigative Dermatology, 136(1):339-342.

Merlino, Glenn; Herlyn, Meenhard; Fisher, David E; Bastian, Boris C; Flaherty, Keith T; Davies, Michael A; Wargo, Jennifer A; Curiel-Lewandrowski, Clara; Weber, Michael J; Leachman, Sancy A; Soengas, Maria S; McMahon, Martin; Harbour, J. William; Swetter, Susan M; Aplin, Andrew E; Atkins, Michael B; Bosenberg, Marcus W; Dummer, Reinhard; Gershenwald, Jeffrey E; Halpern, Allan C; Herlyn, Dorothee; Karakousis, Giorgos C; Kirkwood, John M; Krauthammer, Michael; Lo, Roger S; Long, Georgina V; McArthur, Grant; Ribas, Antoni; Schuchter, Lynn; Sosman, Jeffrey A; Smalley, Keiran S; Steeg, Patricia; Thomas, Nancy E; Tsao, Hensin; Tueting, Thomas; Weeraratna, Ashani; Xu, George; Lomax, Randy; Martin, Alison; Silverstein, Steve; Turnham, Tim; Ronai, Ze'ev A (2016). The state of melanoma: challenges and opportunities. Pigment Cell & Melanoma Research, 29(4):404-416.

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Sondak, Vernon K; Wolchok, Jedd D; Hudson, Andrew M (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, 16(1):15-17.

McArthur, Grant A; Chapman, Paul B; Robert, Caroline; Larkin, James; Haanen, John B; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbé, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J; Kirkwood, John M; Eggermont, Alexander M; Dréno, Brigitte; Sosman, Jeffrey A; Flaherty, Keith T; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, 15(3):323-332.

Flaherty, Keith T; Hennig, Michael; Lee, Sandra J; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M M; Hauschild, Axel; Kefford, Richard; Kirkwood, John M; Long, Georgina V; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant; O'Day, Steven; Patel, Poulam M; Robert, Caroline; Schadendorf, Dirk (2014). Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, 15(3):297-304.

This list was generated on Mon Dec 11 18:38:13 2017 CET.